Skip to main content
. 2014 Aug 27;9(8):e105886. doi: 10.1371/journal.pone.0105886

Figure 6. Treatment of CB42 subcutaneous allografts (n = 10 per treatment arm) and subsequent metastasis to the lung in nude mice with targeted therapy.

Figure 6

A). MET inhibitor crizotinib did not inhibit CB42 tumor growth. B). CDK4/6 inhibitor PD0332991 significantly inhibited CB42 tumor growth (***P<0.001). C). MEK1/2 inhibitor PD0325901 completely blocked CB42 tumor growth (***P<0.001). D). Combination of CDK4/6 and MEK1/2 inhibitor induced CB 42 tumor regression (****P<0.0001). E). Subcutaneous tumor volumes of the three treatment arms at the end of study. The combination is significantly more potent than CDK4/6 inhibitor alone (****P<0.0001) or the MEK inhibitor alone (***P<0.001). F). Gross examination of lung lobes for metastatic nodules revealed that both CDK4/6 inhibitor and MEK inhibitor significantly inhibited CB42 lung metastasis (*P<0.05), but the combination was significantly more effective than either agent alone (****P<0.0001) and almost completely eliminated lung metastasis.